However, unlike HER2, the evaluation criteria for c-MET expression as determined by IHC have not been fully elucidated in patients with GC. 12 We performed a systematic review and meta-analysis to elucidate the correlation between the overexpression of c-MET as determined by IHC and the clinicopathological parameters. In addition, the diagnostic accuracy of IHC was investigated using concordance analysis and performing a review of the diagnostic test accuracy.
Materials and Methods
Published study search and selection criteria
Articles relevant to the subject of the analysis were obtained by searching the PubMed and MEDLINE databases throughout January 31, 2016 using the following key words: 'MET' or 'mesenchymal epithelial transition' and 'IHC'. The titles and abstracts of all the searched articles were screened for exclusion.
The review articles were also screened to identify additional eligible studies. Subsequently, the search results were reviewed and studies were included in the analyses if (1) the study was performed in human cases of GC and (2) information about the correlation between c-MET expression as determined by IHC and clinicopathological parameters, and the amplification of the c-MET gene was available. The articles were excluded if (1) they were case reports or non-original articles or (2) they were published in a language other than English.
Data extraction
The data from all eligible studies were extracted by two independent authors and the extracted data were the first author's name, year of publication, study location, antibody clone and manufacturer, antibody dilution ratio, evaluation criteria, number of patients analyzed, and the data allowing the estimation of the impact of c-MET overexpression as determined by IHC on overall survival (OS). For the meta-analysis, we extracted all the data associated with the results of the IHC analyses.
Statistical analysis
For the meta-analysis, all data were analyzed using the the hazard ratios (HRs) that were obtained using one of three available methods. For studies lacking information on the HR or its confidence interval (CI), these variables were calculated from the presented data using the HR point estimate, log-rank statistic or its P-value, and the O-E statistic (the difference between the number of observed and expected events) or its variance. If data on the HR values were not available, they were estimated using the total number of events, number of patients at risk in each group, and the log-rank statistic or its P-value. Finally, if useful data were provided only in the form of graphical illustrations of survival distributions and survival rates, these data were extracted at specified time points to reconstruct the HR estimate and its variance under the assumption that the patients were censored at a constant rate during the time intervals. 50 The published survival curves were read independently by two authors IHC = immunohistochemistry; N = number of patients; OE = overexpression; GA = genetic alteration; ND = no description; mod = moderate intensity; SISH = silver in situ hybridization; PCR = polymerase chain reaction; weak = weak intensity; strong = strong intensity; NGS = nextgeneration sequencing; FISH = fluorescence in situ hybridization; CISH = chromogenic in situ hybridization. *The combination of intensity and fraction scores.
in order to reduce the interpretation bias. Subsequently, the HRs were combined into an overall HR using the Peto method. 51 Because eligible studies used various clones of the c-MET antibody and different evaluation criteria for various patient populations, a random-effects model was more suitable than a fixed-effects model. The heterogeneity between the studies was assessed using the Q and I 2 statistics, and the results were presented as Pvalues. Additionally, sensitivity analysis was performed to assess the heterogeneity of eligible studies and the impact of each study on the combined effect. In order to assess the publication bias, a
Begg funnel plot and Egger test were used. If a significant publication bias was identified, the fail-safe N and trim-fill tests were performed to confirm the degree of publication bias. P<0.05
were considered to be statistically significant.
The review of diagnostic test accuracy was performed using the Meta-Disc program version 1.4 (Unit of Clinical Biostatics; the Ramon y Cajal Hospital, Madrid, Spain). 52 In order to calculate the pooled sensitivity and specificity, data were collected from each eligible study and forest plots were obtained.
The summary receiver operating characteristic (SROC) curve was initially constructed by plotting 'sensitivity' and '1-specificity' of each study, and curve fitting was performed through linear regression using the Littenberg and Moses linear models. 53 Because the data were heterogeneous owing to differences in the evaluation criteria, the accuracy data were pooled by fitting a SROC curve and measuring the value of the area under the curve (AUC). 52 An AUC close to 1 would be considered a perfect fit and an AUC close to 0.5 would be considered a poor fit.
In addition, the diagnostic odds ratio (OR) was calculated using the Meta-Disc program.
Results

Study selection and characteristics
In total, 3,010 reports were identified in the database search for this systematic review and meta-analysis. Among them, 77
were excluded owing to insufficiency or lack of information on the correlation between c-MET overexpression as determined by IHC and the clinicopathological parameters, and the amplification of c-MET. In addition, 2,876 reports were excluded because they were concerning other diseases, or they used animals or cell lines, and 20 were excluded because they were articles written in a language other than English or they were non-original articles. Finally, 37 studies were included in this systematic review and meta-analysis (Table 1 , Fig. 1 ). The total number of patients from the 37 studies was 8,395. patients) in the present study.
Clinicopathological significance of c-MET overexpression as determined by immunohistochemistry
The estimated c-MET overexpression rate as determined by IHC was 0.403 (95% CI, 0.327~0.484) ( Table 2 However, in cases showing c-MET overexpression, the concordance rate of the high evaluation criteria subgroup (0.082; 95% CI, 0.016~0.334) was significantly lower than that of the other subgroups. There was no significant publication bias in the primary and secondary tests.
Diagnostic accuracy of c-MET immunohistochemistry
Next, a diagnostic accuracy test review was performed. In all cases, the pooled sensitivity and specificity were 0.56 (95% CI, 0.50~0.63) and 0.79 (95% CI, 0.77~0.81), respectively ( Table 5 ).
The sensitivity and specificity of the eligible studies were 0.25 to In the eligible studies, the rates of c-MET overexpression and c-MET amplification were 31.5% (2,641 out of 8,395 patients) and 11.5% (232 out of 2,019 patients), respectively. There cancer. 12 However, further studies should be conducted to determine the accurate evaluation criteria to reduce the false positive rate.
Interestingly, in the non-overexpressed c-MET cases, the concordance rate of eligible studies with low staining was lower than that of eligible studies with high staining. In our unpublished data for non-small cell lung cancer, the concordance rate between c-MET expression and c-MET amplification was lower in the low expression group than in the high criteria group. In the present diagnostic test accuracy review, the estimates of the studies with low criteria for diagnostic accuracy were lower than that of studies with other criteria, as shown Table 5 . In addition, in clinical trials with patients classified according to their c-MET expression status, rilotumumab showed a therapeutic effect for GC. 54 In that study, c-MET overexpression was evaluated at >25% of membrane staining and any intensity. Because the differences of evaluation criteria might have had an impact on the selected patients and the results for therapeutic effect, more detailed and accurate criteria for c-MET expression are required.
Previously, two studies reported a correlation between c-MET and survival rate through meta-analysis. However, the The eligible studies differed in their follow-up periods. In the present meta-analysis, to avoid bias from the follow-up periods, survival data were extracted after a 60-month follow-up period.
Although the follow-up period did not influence the correlation between c-MET overexpression and survival, the correlation between c-MET and survival differed from those in previous reports. Interestingly, the HRs of eligible studies before 2011
were higher than those of eligible studies after 2012 year. However, the reason for the differences associated with the study year could not be elucidated. Indeed, there were no differences between the c-MET overexpression, study location, and evaluation criteria.
The coexpression of HER2 and c-MET was found in 12% of the GCs. 27 Previous studies have reported that c-MET activation was associated with the resistance against molecular targeted inhibitory therapy for epidermal growth factor receptor.
57-59
Chen et al. 60 has reported that GC cells can evade lapatinibinduced growth inhibition through the activation of MET and reactivation of the downstream signaling pathways. However, a synergistic effect by the dual inhibition of HER2 and MET was not found in GC cells. 60 They concluded that dual inhibition is not required until the development of resistance. 60 In our metaanalysis, the overexpression rate of c-MET in HER2 positive cases was significantly higher than that of the HER2 negative cases (0.349; 95% CI, 0.183~0.563 vs. 0.148; 95% CI, 0.074~0.275, respectively). This result could be useful for elucidating the correlation between c-MET and HER2 and for appropriate patient selection for HER2 or MET monoclonal antibody therapy. In addition, further cumulative studies are required to confirm the detailed mechanism.
There were some limitations to the current meta-analysis.
First, as described above, eligible studies used various antibody clones and evaluation criteria for evaluating the expression status of c-MET. Additional subgroup analysis based on antibody clones could not be performed due to insufficient information.
However, in sensitivity analysis, individual studies had no effects on the pooled estimates. Second, as a confirmatory test for c-MET amplification, various molecular tests, such as fluorescence ISH, silver ISH, chromogenic ISH, polymerase chain reaction, and next generation sequencing, were used. However, the diagnostic accuracy of c-MET IHC analysis according to the molecular test could not be evaluated due to insufficient information.
Third, as described above, the concordance rate of low criteria group between c-MET expression and c-MET amplification was lower than that of other criteria groups. However, 2 of the eligible studies were using high and other criteria, respectively.
Because the minimum number of included studies was 3 for the diagnostic test accuracy review, a subgroup analysis of the high and other criteria could not be performed. In order to evaluate the diagnostic accuracy of the low criteria for c-MET expression, we subdivided and compared the low and others subgroups.
In conclusion, this study showed that the overexpression of 
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